学术探索
学术期刊
新闻热点
数据分析
智能评审

DISPOSITION, METABOLISM AND PHARMACOKINETICS OF ANTIHYPERLIPIDEMIC AGENTS IN LABORATORY-ANIMALS AND MAN

被引：45
作者：
CAYEN, MN
机构：
来源：
PHARMACOLOGY & THERAPEUTICS | 1985年 / 29卷 / 02期
关键词：
D O I：
10.1016/0163-7258(85)90028-2
中图分类号：
R9 [药学];
学科分类号：
1007 ;
摘要：
引用
收藏
页码：157 / 204
页数：48
相关论文
共 412 条
[1]   DISPOSITION PHARMACOKINETICS OF BEZAFIBRATE IN MAN [J].
ABSHAGEN, U ;
BABLOK, W ;
KOCH, K ;
LANG, PD ;
SCHMIDT, HAE ;
SENN, M ;
STORK, H .
EUROPEAN JOURNAL OF CLINICAL PHARMACOLOGY, 1979, 16 (01) :31-38
[2]   STEADY-STATE KINETICS OF BEZAFIBRATE AND CLOFIBRATE IN HEALTHY FEMALE VOLUNTEERS [J].
ABSHAGEN, U ;
SPORLRADUN, S ;
MARINOW, J .
EUROPEAN JOURNAL OF CLINICAL PHARMACOLOGY, 1980, 17 (04) :305-308
[3]   PHARMACOKINETICS OF BEZAFIBRATE AFTER SINGLE AND MULTIPLE DOSES IN THE PRESENCE OF RENAL-FAILURE [J].
ABSHAGEN, U ;
KOSTERS, W ;
KAUFMANN, B ;
LANG, PD .
KLINISCHE WOCHENSCHRIFT, 1980, 58 (17) :889-896
[4]   PLASMOLYSIS, RED-BLOOD-CELL PARTITIONING, AND PLASMA-PROTEIN BINDING OF ETOFIBRATE, CLOFIBRATE, AND THEIR DEGRADATION PRODUCTS [J].
ALTMAYER, P ;
GARRETT, ER .
JOURNAL OF PHARMACEUTICAL SCIENCES, 1983, 72 (11) :1309-1318
[5]  
AMBROGI V, 1980, EUR J MED CHEM, V15, P157
[6]   CLINICAL PHARMACOKINETICS OF BEZAFIBRATE IN PATIENTS WITH IMPAIRED RENAL-FUNCTION [J].
ANDERSON, P ;
NORBECK, HE .
EUROPEAN JOURNAL OF CLINICAL PHARMACOLOGY, 1981, 21 (03) :209-214
[7]  
ANDERSSON RGG, 1977, ACTA PHARMACOL TOX, V41, P1
[8]  
ARAKAWA M, 1978, BIOCHEM PHARMACOL, V27, P167
[9]  
ARNOLD JA, 1970, FED PROC, V29, pA356
[10]  
AVOGARO P, 1978, PHARMACOL RES COMMUN, V10, P127
12345678910